DarioHealth (DRIO) investor relations material

Platform overview and market opportunity

• AI-powered, multi-condition platform addresses cardiometabolic, behavioral, and musculoskeletal care, supporting up to 6+ conditions with bundled pricing at $74 per engaged member per month.

• Serviceable addressable market estimated at over $250 billion, with rapid expansion enabled by platform architecture.

• 76% of U.S. adults have a chronic disease, and 51% have two or more comorbid conditions, highlighting significant demand.

• Blue-chip client base includes 160+ clients, such as Fortune 100 employers and national health plans.

• Channel partnerships provide access to approximately 116 million covered lives, accelerating market penetration.

Product features and engagement

• Integrated digital platform combines connected devices, AI-powered coaching, community support, and clinical services for personalized care.

• Comprehensive support for diabetes, hypertension, weight management, musculoskeletal, behavioral health, and GLP-1 management.

• Average member retention rate after 12 months is 75%, with members using an average of 2.4 solutions.

• Proprietary AI model achieves 90% accuracy in predicting blood sugar fluctuations and delivers a 20% increase in engagement for hypertension management.

• 100+ published peer-reviewed studies validate clinical outcomes and ROI.

Financial performance and growth

• FY2025 revenue reached $22.4M, with Q4 resuming sequential growth and a 10% organic YoY increase.

• Non-GAAP gross margin for B2B2C business is approximately 80%, with a 28% YoY reduction in GAAP OpEx.

• $12.9M in new and soon-to-be-closed ARR contracts, contributing to 2026-2027 growth.

• $122M pipeline of commercial opportunities, with 70% focused on multi-condition contracts.

• Targeting cashflow breakeven by mid-2027, with a 30% decrease in non-GAAP operating loss expected in 2026.